KYAT1 and cancer: Some inhibitors of GTK/KAT1 (based on kynurenine as amino acid transaminase substrate) have been designed with Ki values ranging from ~20 μM to ~1 mM [51] but, to our knowledge, have not been tested as anti-cancer agents.